Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2004

01-12-2004 | Report

Association between the T27C polymorphism in the cytochrome P450 c17α (CYP17) gene and risk factors for breast cancer

Authors: Chi-chen Hong, Henry J. Thompson, Cheng Jiang, Geoffrey L. Hammond, David Tritchler, Martin Yaffe, Norman F. Boyd

Published in: Breast Cancer Research and Treatment | Issue 3/2004

Login to get access
Metadata
Title
Association between the T27C polymorphism in the cytochrome P450 c17α (CYP17) gene and risk factors for breast cancer
Authors
Chi-chen Hong
Henry J. Thompson
Cheng Jiang
Geoffrey L. Hammond
David Tritchler
Martin Yaffe
Norman F. Boyd
Publication date
01-12-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-0780-7

Other articles of this Issue 3/2004

Breast Cancer Research and Treatment 3/2004 Go to the issue

Report

Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats

Report

Increased frequency of long androgen receptor CAG repeats in male breast cancers

Report

Central nervous system metastases in women after multimodality therapy for high risk breast cancer

Commentary

The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality

Report

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients

Report

Integrin β3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control study in Germany
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits